Trial Profile
EVEROLIMUS VERSUS MYCOPHENOLIC ACID IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE DIFFERENCES IN RETINAL NEOVASCULARIZATION IN PATIENTS WITH DIABETIC RETINOPATHY EVEROLIMUS VERSUS MYKOFENOLOVÁ KYSELINA U PACIENTŮ PO KOMBINOVANÁ TRANSPLANTACI LEDVINY A SLINIVKY BŘIŠNÍ ZA ÚČELEM ZHODNOCENÍ VÝVOJE NOVOTVORBY CÁV NA SÍTNICI U PACIENTŮ S DIABETICKOU RETINOPATIÍ
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Mycophenolate sodium (Primary)
- Indications Kidney-pancreas transplant rejection
- Focus Therapeutic Use
- Acronyms EMA-SPK
Most Recent Events
- 23 Sep 2022 Primary endpoint (Occurrence of blindness) has been met, according to Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
- 23 Sep 2022 Primary endpoint (Worsening of visual acuity of more than 2 rows of Snellens optotypes) has been met, according to Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
- 23 Sep 2022 Primary endpoint (Newly diagnosed clinically significant macular edema) has been met, according to Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.